EMA Medicine safety communications
Imbruvica: post-authorisation measure
Published by European Medicines Agency: · Ref. EMEA/H/C/003791/II/0075
Summary
Post-authorisation measure
Medicine
Imbruvica
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): Ibrutinib
- Therapeutic area: Lymphoma, Mantle-Cell;Leukemia, Lymphocytic, Chronic, B-Cell
- ATC code: L01EL01
Measures and alternatives
- Regulatory outcome: Variation
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗